Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane

• DOI: 10.1097/fpc.0b013e3283606cb2
• Publication Date: 2013-03-22T22:31:56Z
• Authors: Antonio D’Avolio; Silvia De Francia; Vittoria Basile; Jessica Cusato; Francesca De Martino; Elisa Pirro; Francesca Piccione; Arianna Ardito; Barbara Zaggia; Marco Volante; Giovanni Di Perri; Massimo Terzolo
• Keywords: Mitotane; CYP2B6; Vismodegib; Bioequivalence

The aim of this study was to assess the potential impact pharmacogenetic variability CYP2B6 and ABCB1 genes on pharmacokinetics mitotane.A retrospective analysis carried out 27 patients with adrenocortical carcinoma postoperative adjunctive mitotane. polymorphisms were genotyped tested for an association plasma trough concentration after 3, 6, 9, 12 months therapy.Patients GT/TT genotype had higher mitotane concentrations compared GG at 3 (14.80 vs. 8.01 μg/ml; P=0.008) 6 (17.70 9.75 P=0.015). Multivariate logistic regression showed that only rs3745274GT/TT (odds ratio=10.7; P=0.017) a predictor least 14 µg/ml treatment. Mitotane not influenced by gene.Evaluation polymorphism enabled prediction individual response adjuvant